Investor Presentation Q1-Q3 2020

30 Investor presentation First nine months of 2020 Novo NordiskⓇ Novo Nordisk holds solid patent protection, high barriers to entry, and a collaborative approach to innovation Novo Nordisk's position is protected by patents and value chain setup OZEMPİC semaglutide injection RYBELSUS® semaglutide tablets m Fiasp fast-acting insulin aspart esperoct turoctocog alfa pegol Xultophy insulin degludaciraglutide IrDNA origin injection EU/US patent protection1 20312 • 20312,3 20304 • • 2034/322 Barriers to entry for biosimilar players Research & Development Need to show comparability in PK/PD trials Strict regulatory requirements in the EU and the US Requirement for both drug and device offering Manufacturing Economies of scale Up-front CAPEX requirements with slow return on investment Partnerships and acquisitions support future R&D siRNA treatments TM Dicerna Novel treatments Combination treatments for NASH GILEAD Gene editing for haemophilia for CVD 2028/29 Commercialisation TRESIBA insulindegiudec DNA origin injection • Large and fragmented target audience STATEN 2028/29 BIOTECHNOLOGY CORVIDIA Cost pressure from payers on Carlosaarheezoutes RYZODEG 70% insulindegudec and 30% insulinaspart DNA annection refixia® VICTOZA 2028/29 On-going conversion to next-generation drugs and slow market dynamics 2027/282 2023 bluebirdbio recode for life" 1 List does not include all marketed products. 2 Current estimates; 3 Tablet formulation and once-daily treatment regimen are protected by additional patents expiring in 2031-2034; 4 Formulation patent; active ingredient patent has expired; SaxendaⓇ patent identical to VictozaⓇ patent. PK: Pharmacokinetic, PD: Pharmacodynamic; CAPEX: Capital expenditure; siRNA: Silencing ribonucleic acid; NASH: Non-alcoholic steatohepatitis; CVD: Cardiovascular disease

View entire presentation